Streetbeat News

Analyst Ratings

PCAR

Goldman Sachs analyst Jerry Revich has maintained a Neutral rating on PACCAR (NASDAQ:PCAR) and increased the price target from $93 to $106.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 6:15 pm

NFLX

Goldman Sachs analyst Eric Sheridan has maintained a Neutral rating on Netflix (NASDAQ:NFLX) but increased the price target from $500 to $565.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 6:14 pm

IVZ

Goldman Sachs analyst Alexander Blostein has maintained a Neutral rating on Invesco (NYSE:IVZ) and reduced the price target from $18 to $17.25.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 6:12 pm

DD

Wells Fargo analyst Michael Sison has downgraded DuPont de Nemours (NYSE:DD) from Overweight to Equal-Weight and reduced the price target from $85 to $69.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 6:09 pm

DXC

DXC Technology (NYSE:DXC) has been evaluated by 4 analysts over the past three months, with a shift towards a more bearish stance. The average 12-month price target has been lowered by 12.38% to $23.00, with a high estimate of $24.00 and a low of $21.00. Analysts from JP Morgan, Citigroup, BMO Capital, and RBC Capital have all lowered their price targets. DXC Technology's financial performance shows a decline in revenue growth, below-average net margin and ROE, and a high debt-to-equity ratio, indicating potential financial challenges.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 6:00 pm

MMM

Five analysts have recently updated their ratings on 3M (NYSE:MMM), with four maintaining an indifferent stance and one rating it as somewhat bearish. The average 12-month price target is now $103.2, up from $102.60, with individual analysts adjusting their targets both upwards and downwards. 3M's financials show a revenue decline of -3.56%, a high net margin of -24.96%, an ROE of -33.28%, an ROA of -4.21%, and a debt-to-equity ratio of 3.6, indicating mixed financial health and potential risks.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 6:00 pm

MGNX

Macrogenics (NASDAQ:MGNX) received mixed reviews from 5 analysts, with recent ratings ranging from bullish to somewhat bullish. The average 12-month price target is $14.00, a significant increase from the previous $10.33. Analysts from JMP Securities, Citigroup, Stifel, HC Wainwright & Co., and Guggenheim have adjusted their price targets and ratings, reflecting changes in market dynamics and company performance. Macrogenics, a biotech company specializing in antibody-based cancer therapeutics, has a market cap below industry benchmarks and experienced a significant revenue decline of -75.09% over the last quarter. However, it has a high net margin of 168.84%, an ROE of 9.6%, and an ROA of 5.44%, indicating strong profitability and financial management.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 6:00 pm

CCBG

Capital City Bank's stock (CCBG) is trading higher following an upgrade from Neutral to Buy by Janney Montgomery Scott.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 5:32 pm

YOU

Needham analyst Joshua Reilly has reiterated a Buy rating on Clear Secure (NYSE:YOU) and maintained a $40 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 5:31 pm

AAL

ALK

BA

SKYW

American Airlines (AAL) and Alaska Air (ALK) are set to report Q4 earnings on Jan. 25. AAL's stock is down 12% over the past year with expected EPS of 10 cents and $13.02 billion in revenue. ALK's stock is down 28% after a mid-air incident involving a Boeing 737 Max 9, with expected EPS of 18 cents and $2.55 billion in revenue. AAL has a global presence but high debt levels, while ALK has a strong West Coast presence and healthier balance sheet. Analysts predict more upside potential for ALK than AAL.

Portfolio Pulse from Surbhi Jain

January 24, 2024 | 5:28 pm